ViraxImmune™ — Topline data
2026
The investor presentation sets out a validation-led timeline with 2026 focused on readout and partner study preparation.Source filing
VIRAX BIOLABS GROUP LTD · Data as of 2026-09-08
2026
The investor presentation sets out a validation-led timeline with 2026 focused on readout and partner study preparation.Source filing
Q1 2027
• Virax is preparing for its next major development milestone: a larger clinical validation analysis involving previously collected samples from 300 additional participants, with analysis expected to begin in Q4 2026 and results expected in Q1 2027.Source filing